Leukotriene Pathway Activation Associates with Poor Glycemic Control and with Cardiovascular Autonomic Neuropathy in Type 1 Diabetes

Figure 2

Expressions of ALOX5, MYD88, and LTB4R mRNA in peripheral blood mononuclear cells (a–c) and plasma concentrations of leukotriene B4 (LTB4) (d) in type 1 diabetes (T1D) individuals sorted by the presence or absence of microvascular complications (adjusted for sex, age, HbA₁C, diabetes duration, and use of angiotensin-converting enzyme inhibitor, angiotensin receptor blocker, and statin). In (e), plasma concentrations of LTB4 are shown in T1D individuals sorted by the presence or absence of cardiac autonomic neuropathy (CAN) (adjusted for the same aforementioned confounders plus diabetes retinopathy, peripheral neuropathy, and diabetes kidney disease).

(a)

(b)

(c)

(d)

(e)